GILD Share Price Performance
US$124.99
35.23 (39.25%)
3.5% undervalued intrinsic discount
US$129.51
Fair Value
Price US$124.99
AnalystConsensusTarget US$129.51
AnalystHighTarget US$140.92
AnalystLowTarget US$91.00
Fair ValueUS$129.51
Share Pricen/a
Gilead Sciences, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 234 Fair Values set on narratives written by author
GILD Community Narratives
AN
Fair Value US$129.51 3.5% undervalued intrinsic discount
Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
1users have liked this narrative
0users have commented on this narrative
105users have followed this narrative
AN
Fair Value US$140 10.7% undervalued intrinsic discount
Lenacapavir And Trodelvy Launches Will Serve A Growing Aging Market
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value US$91.83 36.1% overvalued intrinsic discount
Biktarvy And Lenacapavir Launches Will Drive Cautious Future Progress
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
Key Takeaways New product launches and expanded global access are driving revenue growth and improving Gilead's product mix, reducing reliance on legacy drugs. Strong cash flow and disciplined expense management enable share buybacks and margin expansion, supporting sustainable earnings and capital returns.Read more
1users have liked this narrative
0users have commented on this narrative
105users have followed this narrative
AN
US$129.51
3.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
4.16% p.a.
Profit Margin
31.14%
Future PE
19.18x
Share price in 2028
US$159.71
Lenacapavir And Trodelvy Launches Will Serve A Growing Aging Market
Key Takeaways Multiple new product launches and innovation in oncology and HIV therapy strongly position Gilead to expand into larger, diversified markets and drive sustained revenue growth. Strength in core HIV and liver portfolios, robust R&D, and minimal competition risks support stable cash flows and enable long-term margin and earnings expansion.Read more
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
US$140
10.7% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
5.64% p.a.
Profit Margin
32.03%
Future PE
19.51x
Share price in 2028
US$170.63
Biktarvy And Lenacapavir Launches Will Drive Cautious Future Progress
Key Takeaways Expected headwinds from Medicare Part D redesign may hinder HIV treatment revenue, leading to flat sales projections. Increased competition in oncology and cell therapy could affect revenue growth across diverse product lines.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$91.83
36.1% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
1.59% p.a.
Profit Margin
26.83%
Future PE
17.02x
Share price in 2028
US$110.91
Recently Updated Narratives
AN
Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
Fair Value: US$129.51 3.5% undervalued intrinsic discount
105 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Lenacapavir And Trodelvy Launches Will Serve A Growing Aging Market
Fair Value: US$140 10.7% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Biktarvy And Lenacapavir Launches Will Drive Cautious Future Progress
Fair Value: US$91.83 36.1% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Gilead Sciences, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 6.54
- 78.72%
- 27.88%
- 116.2%
About GILD
- Founded
- 1987
- Employees
- 17600
- CEO
- WebsiteView website
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
